Investigational Therapeutic Genital Herpes Vaccine Promising

An investigational therapeutic genital herpes vaccine has shown significant antiviral activity in a phase 2 trial, said researchers speaking at the American Academy of Dermatology (AAD) 74th Annual Meeting. The vaccine, currently named GEN-003, is a first-in-class immunotherapy composed of two immunogenic antigens and a matrix adjuvant, designed to induce both T-cell and B-cell immune responses. In the phase 2, randomized, double-blind, placebo-controlled study, 310 patients with herpes simplex virus 2 infection were randomly assigned to one of seven dose groups: 30 or 60 ?g of antigen combined with 25, 50, or 75 ?g adjuvant, or placebo. At 6 months, statistically significant reductions in viral shedding were seen in all the active vaccine groups. The most effective dose combination was the 60 ?g antigen/75 ?g adjuvant, which showed a 55% reduction in shedding. Significant reductions in lesions were also seen in all active vaccine doses, as well as with placebo.

Mais detalhes em:
http://www.medscape.com/viewarticle/859925?nlid=101803_2243&src=WNL_mdplsnews_160311_mscpedit_infd&uac=191521PN&spon=3&impID=1019272&faf=1

Mais informações sobre o estudo podem ser encontradas no site https://www.clinicaltrials.gov.

Leia mais em português:
http://www.news-medical.net/news/20151007/612/Portuguese.aspx